IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Related Articles
OST-HER2 Extends 12-Month EFS in Osteosarcoma With Lung Metastases
OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung…
Youtube Icon
Optimizing Treatment Strategies for Localized and Advanced Genitourinary MalignanciesPresented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education.
Fox Chase Cancer Center Scientist Yash Chhabra Honored With NextGen Stars Award From American Association for Cancer Research
PHILADELPHIA (January 21, 2025) — Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently…
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups,…
AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
Breast cancer survivors with BRCA mutations at greater risk for second primary malignancies
Breast cancer survivors who harbor BRCA gene mutation are at elevated risk for second primary cancers, according to study results.These individuals likely would benefit from…
Cold air makes oxygen toxic for worms
A new study from a postbaccalaureate researcher in Mark Roth’s lab at Fred Hutch Cancer Center, Cameron Suraci, shows that microscopic worms exposed to frigid…
2024 Year in Review
Leonidas Platanias, MD, PhD Director, Lurie Cancer Center In 2024, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University continued to advance our understanding…
A Pragmatist’s View on Biomarker-Driven Decisions in Oncology: Episode 2
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Clinical Insights | JCO Oncology Practice
This clinical insights article is derived from recommendations in Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. This document is based on…
